Cameron Santoro

Here are the top 5 biosimilar articles for the week of July 1, 2024.

In an interview with Jeffrey Casberg, MS, RPh, he discusses 3 promising specialty drugs coming through the pipeline. Casberg explains these drugs offer new treatment options for major diseases and stakeholders should watch for their potential impact on the market.

Here are the top 5 biosimilar articles for the week of June 24, 2024.

Jeffrey Casberg, RPh, MS, from IPD Analytics, explains why he believes policy changes and market forces are impacting the cost of drugs, including the Inflation Reduction Act (IRA) and pharmacy benefit manager (PBM) legislation.

Here are the top 5 biosimilar articles for the week of June 17, 2024.

Part 2 of this series dives into the health care system, revealing financial hurdles that limit biosimilar access and ultimately hinder health equity.

Here are the top 5 biosimilar articles for the week of June 10, 2024.

Switching patients with non-infectious uveitis from originator adalimumab to biosimilar adalimumab-atto was safe and effective, but some patients experienced the nocebo effect, where negative adverse events are caused by patients’ poor perception of the drug rather than the medication itself.

Here are the top 5 biosimilar articles for the week of June 3, 2024.

Here are the top 5 biosimilar articles for the week of May 27, 2024.

Here are the top 5 biosimilar articles for the week of May 20, 2024.

Here are the top 5 biosimilar articles for the week of May 13, 2024.

A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.

Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, showcasing certain drugs that will face competition soon.

Here are the top 5 biosimilar articles for the week of May 6, 2024.

Biosimilars offer a promising path to affordable, effective treatment, but barriers remain for underserved communities. This 2-part series explores the potential of biosimilars to improve health equity while addressing the obstacles that currently prevent access.

Here are the top 5 biosimilar articles for the week of April 29, 2024.

In an interview with Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy focuses on biosimilar interchangeability and approaches to encourage wider adoption in dispensing these medications.

Here are the top 5 biosimilar articles for the week of April 22, 2024.

Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.

Ha Kung Wong, JD, a patent attorney, explores the challenges of "patent thickets" in the biologics market, where a complex web of patents can hinder development of more affordable biosimilar drugs. However, the discussion also highlights mechanisms to ensure fair competition and patient access.

Here are the top 5 biosimilar articles for the week of April 15, 2024.

Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.

Here are the top 5 biosimilar articles for the week of April 8, 2024.

Intellectual property attorney Ha Kung Wong, JD, describes the patent dance and how it is designed to streamline information exchange while avoiding unnecessary lawsuits by allowing early assessment of patent infringement and validity.

Here are the top 5 biosimilar articles for the week of April 1, 2024.

Here are the top 5 biosimilar articles for the week of March 25, 2024.

Switching to the biosimilar version of tocilizumab (BAT1806/BIIB800) showed similar effectiveness, safety, and tolerability compared with the original drug for patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate.

Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.

Ha Kung Wong, JD, an intellectual property attorney, discusses lawsuits by drug companies aimed at delaying competition from biosimilars, but the effectiveness of these lawsuits in hindering biosimilar access remains uncertain.